| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5297 | 2021 |
| Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis V Makarov, G Manina, K Mikusova, U Möllmann, O Ryabova, ... Science 324 (5928), 801-804, 2009 | 841 | 2009 |
| Methods for the integration of multi-omics data: mathematical aspects M Bersanelli, E Mosca, D Remondini, E Giampieri, C Sala, G Castellani, ... BMC bioinformatics 17, 167-177, 2016 | 404 | 2016 |
| Mycobacterium tuberculosis differentially activates cGAS-and inflammasome-dependent intracellular immune responses through ESX-1 R Wassermann, MF Gulen, C Sala, SG Perin, Y Lou, J Rybniker, ... Cell host & microbe 17 (6), 799-810, 2015 | 385 | 2015 |
| Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota F Durazzi, C Sala, G Castellani, G Manfreda, D Remondini, A De Cesare Scientific reports 11 (1), 3030, 2021 | 308 | 2021 |
| Towards a new tuberculosis drug: pyridomycin–nature's isoniazid RC Hartkoorn, C Sala, J Neres, F Pojer, S Magnet, R Mukherjee, ... EMBO molecular medicine 4 (10), 1032-1042, 2012 | 208 | 2012 |
| Extremely potent human monoclonal antibodies from COVID-19 convalescent patients E Andreano, E Nicastri, I Paciello, P Pileri, N Manganaro, G Piccini, ... Cell 184 (7), 1821-1835. e16, 2021 | 191 | 2021 |
| Lansoprazole is an antituberculous prodrug targeting cytochrome bc1 J Rybniker, A Vocat, C Sala, P Busso, F Pojer, A Benjak, ST Cole Nature communications 6 (1), 7659, 2015 | 181 | 2015 |
| Commensal-driven immune zonation of the liver promotes host defence A Gola, MG Dorrington, E Speranza, C Sala, RM Shih, AJ Radtke, ... Nature 589 (7840), 131-136, 2021 | 173 | 2021 |
| Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes M Bersanelli, E Travaglino, M Meggendorfer, T Matteuzzi, C Sala, ... Journal of Clinical Oncology 39 (11), 1223, 2021 | 158 | 2021 |
| Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis C Sala, N Dhar, RC Hartkoorn, M Zhang, YH Ha, P Schneider, ST Cole Antimicrobial agents and chemotherapy 54 (10), 4150-4158, 2010 | 157 | 2010 |
| The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis L Solans, J Gonzalo-Asensio, C Sala, A Benjak, S Uplekar, J Rougemont, ... PLoS pathogens 10 (5), e1004183, 2014 | 153 | 2014 |
| Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein B Blasco, JM Chen, R Hartkoorn, C Sala, S Uplekar, J Rougemont, ... PLoS pathogens 8 (3), e1002621, 2012 | 149 | 2012 |
| Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants E Andreano, I Paciello, G Piccini, N Manganaro, P Pileri, I Hyseni, ... Nature 600 (7889), 530-535, 2021 | 133 | 2021 |
| Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion J Rybniker, JM Chen, C Sala, RC Hartkoorn, A Vocat, A Benjak, ... Cell Host & Microbe 16 (4), 538-548, 2014 | 103 | 2014 |
| Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis M Zhang, C Sala, RC Hartkoorn, N Dhar, A Mendoza-Losana, ST Cole Antimicrobial agents and chemotherapy 56 (11), 5782-5789, 2012 | 103 | 2012 |
| The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: a systems biology approach D Calçada, D Vianello, E Giampieri, C Sala, G Castellani, A de Graaf, ... Mechanisms of ageing and development 136, 138-147, 2014 | 99 | 2014 |
| Assessing the essentiality of the decaprenyl‐phospho‐d‐arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants GS Kolly, F Boldrin, C Sala, N Dhar, RC Hartkoorn, M Ventura, A Serafini, ... Molecular microbiology 92 (1), 194-211, 2014 | 92 | 2014 |
| EspC forms a filamentous structure in the cell envelope of Mycobacterium tuberculosis and impacts ESX‐1 secretion Y Lou, J Rybniker, C Sala, ST Cole Molecular microbiology 103 (1), 26-38, 2017 | 90 | 2017 |
| The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis V Singh, S Donini, A Pacitto, C Sala, RC Hartkoorn, N Dhar, G Keri, ... ACS infectious diseases 3 (1), 5, 2017 | 89 | 2017 |
